TABLE 4.
Univariate linear regression model for predicting tumor reduction volume in 14 dogs undergoing TAE for hepatocellular masses.
| Variable | Regression coefficient (95% confidence interval) | p value |
|---|---|---|
| Dog factors | ||
| Age (per 1 year) | −0.840 (−2.208 to 0.528) | .12 |
| Weight (per 1 kg) | −0.654 (−8.539 to 7.231) | .85 |
| Tumor factors | ||
| Hepatic segment (vs left) | ||
| Center | −60.06 (−162.44 to 42.32) | .21 |
| Right | −17.41 (−80.11 to 45.29) | .53 |
| Pre‐TAE tumor volume (per 1 cm3) | 0.066 (−0.041 to 0.174) | .19 |
| Tumor volume/body weight (cm3/kg) | 1.133 (0.200 to 2.066) | .02 † |
| Signs/history | ||
| History of signs of gastrointestinal disease+ (vs −) | −4.78 (−65.79 to 56.31) | .86 |
| History of abdominal effusion+ (vs −) | 31.06 (−30.69 to 92.81) | .28 |
| History of weight loss+ (vs −) | −37.41 (−96.78 to 21.95) | .18 |
| History of hemoabdomen+ (vs −) | 47.83 (−17.95 to 113.6) | .13 |
| History of jaundice+ (vs −) | NA | NA |
| Embolic agent | ||
| Embosphere (vs Gelpart) | 19.68 (−55.09 to 94.44) | .56 |
Abbreviation: TAE, transcatheter arterial embolization.
†
p < .05.